3H-spiperone binding to lymphocytes is increased in schizophrenic patients and decreased in parkinson patients
The binding parameters (Bmax and KD) for the dopamine antagonist 3H-spiperone were investigated in psychiatric patients and in patients with Parkinsonian diesease. Bmax values were found to be increased in acute, unmedicated schizophrenics (n = 46), during neuroleptic treatment (n = 25) and in chronic schizophrenics (n = 6) being under long term neuroleptic treatment. In all other psychiatric patients, including endogenous depressives, manics, neurotics, borderline and alcoholic patients the binding capacity did not differ from that of healthy control persons (n = 50). This finding suggests, that increased 3H-spiperone binding could be valid as marker for schizophrenia.. In contrast to that, 3H-spiperone binding was found to be decreased in drug free (n = 5) and in MAO-B (n = 2) or short term L-DOPA (n = 3) treated Parkinsonian patients (mean decrease 80%) as compared to age and sex matched controls. The significance of the later finding has to be further investigated.
KeywordsSchizophrenic Patient Psychiatric Patient Parkinsonian Patient Neuroleptic Treatment Chronic Schizophrenic
Unable to display preview. Download preview PDF.
- Biziere K, Guillaumin JM, Degenne D, Bardos P, Renoux M, Renoux G (1985) Lateralized neocortical modulation of the T-cell lineage. In: Guillemin R (ed) Neural modulation of immunity. Raven Press, New York, pp 81–93Google Scholar
- Cramer H, Warter JM, Renaud B (1984) Analysis of neurotransmitter metabolites and adenosine 3’, 5’-monophosphate in the CSF of patients with extrapyramisal motor disorders. In: Hassler RG, Christ JF (eds) Advances in neurology, vol 40. Raven Press, New York, pp 431–435Google Scholar
- Guttman M, Seeman P (1986) Dopamine D 2 receptor density in parkinsonian brain is constant for duration of disease, age and duration of L-DOPA therapy. Adv Neurol 45: 51–57Google Scholar
- LeFur G, Meininger VA, Baulac M, Uzan A (1981) Recepteurs dopaminergiques lymphocytaires et maladie de parkinson idiopathique. Rev Neurol 137: 89–96Google Scholar
- Rotstein E, Ram RK, Singal DP, Barone D (1983) Lymphocyte 3H-spiroperidol binding in schizophrenia: preliminary findings. Progr Neuro-Psychopharmac Biol Psychiat 7: 720–723Google Scholar
- Shaskan EG, Ballow M, Oreland L, Wadell G (1983) Is there a functional significance for dopamine antagonist binding on lymphoid cells? Biol Psychiat 12: 123–145Google Scholar